Selected research
Industry Research
Lyme Disease Testing Industry Research Report 2026
Market perspective
The global Lyme Disease Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Lyme Disease Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Lyme Disease Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Lyme Disease Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Lyme Disease Testing include Quidel Corporation, Roche Holding AG, Fujirebio(H.U. Group Holdings), ZEUS Scientific, IGeneX, Thermo Fisher Scientific, Everlywell, Oxford Immunotec Global PLC(PerkinElmer) and BioMerieux, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Lyme Disease Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Lyme Disease Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lyme Disease Testing Market by Company
Quidel Corporation
Roche Holding AG
Fujirebio(H.U. Group Holdings)
ZEUS Scientific
IGeneX
Thermo Fisher Scientific
Everlywell
Oxford Immunotec Global PLC(PerkinElmer)
BioMerieux
Bio-Rad Laboratories
T2 Biosystems
Lyme Disease Testing Segment by Type
ELISA
Western Blotting
PCR
Others
Lyme Disease Testing Segment by Application
Hospital and Testing Agency
Personal
Lyme Disease Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lyme Disease Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lyme Disease Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lyme Disease Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Lyme Disease Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ELISA
- Western Blotting
- PCR
- Others
Applications
- Hospital and Testing Agency
- Personal
Companies covered
- Quidel Corporation
- Roche Holding AG
- Fujirebio(H.U. Group Holdings)
- ZEUS Scientific
- IGeneX
- Thermo Fisher Scientific
- Everlywell
- Oxford Immunotec Global PLC(PerkinElmer)
- BioMerieux
- Bio-Rad Laboratories
- T2 Biosystems
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Lyme Disease Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 ELISA
- 2.2.3 Western Blotting
- 2.2.4 PCR
- 2.2.5 Others
- 2.3 Lyme Disease Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital and Testing Agency
- 2.3.3 Personal
- 2.4 Assumptions and Limitations
3 Lyme Disease Testing Breakdown Data by Type
- 3.1 Global Lyme Disease Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Lyme Disease Testing Forecasted Market Size by Type (2027-2032)
4 Lyme Disease Testing Breakdown Data by Application
- 4.1 Global Lyme Disease Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Lyme Disease Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Lyme Disease Testing Market Perspective (2021-2032)
- 5.2 Global Lyme Disease Testing Growth Trends by Region
- 5.2.1 Global Lyme Disease Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Lyme Disease Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Lyme Disease Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Lyme Disease Testing Market Dynamics
- 5.3.1 Lyme Disease Testing Industry Trends
- 5.3.2 Lyme Disease Testing Market Drivers
- 5.3.3 Lyme Disease Testing Market Challenges
- 5.3.4 Lyme Disease Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Lyme Disease Testing Players by Revenue
- 6.1.1 Global Top Lyme Disease Testing Players by Revenue (2021-2026)
- 6.1.2 Global Lyme Disease Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Lyme Disease Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Lyme Disease Testing Head Office and Area Served
- 6.4 Global Lyme Disease Testing Players, Product Type & Application
- 6.5 Global Lyme Disease Testing Manufacturers Established Date
- 6.6 Global Lyme Disease Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Lyme Disease Testing Market Size (2021-2032)
- 7.2 North America Lyme Disease Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Lyme Disease Testing Market Size by Country (2021-2026)
- 7.4 North America Lyme Disease Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Lyme Disease Testing Market Size (2021-2032)
- 8.2 Europe Lyme Disease Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Lyme Disease Testing Market Size by Country (2021-2026)
- 8.4 Europe Lyme Disease Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Lyme Disease Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Lyme Disease Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Lyme Disease Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Lyme Disease Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Lyme Disease Testing Market Size (2021-2032)
- 10.2 South America Lyme Disease Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Lyme Disease Testing Market Size by Country (2021-2026)
- 10.4 South America Lyme Disease Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Lyme Disease Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Lyme Disease Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Lyme Disease Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Lyme Disease Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Quidel Corporation
- 12.1.1 Quidel Corporation Company Information
- 12.1.2 Quidel Corporation Business Overview
- 12.1.3 Quidel Corporation Revenue in Lyme Disease Testing Business (2021-2026)
- 12.1.4 Quidel Corporation Lyme Disease Testing Product Portfolio
- 12.1.5 Quidel Corporation Recent Developments
- 12.2 Roche Holding AG
- 12.2.1 Roche Holding AG Company Information
- 12.2.2 Roche Holding AG Business Overview
- 12.2.3 Roche Holding AG Revenue in Lyme Disease Testing Business (2021-2026)
- 12.2.4 Roche Holding AG Lyme Disease Testing Product Portfolio
- 12.2.5 Roche Holding AG Recent Developments
- 12.3 Fujirebio(H.U. Group Holdings)
- 12.3.1 Fujirebio(H.U. Group Holdings) Company Information
- 12.3.2 Fujirebio(H.U. Group Holdings) Business Overview
- 12.3.3 Fujirebio(H.U. Group Holdings) Revenue in Lyme Disease Testing Business (2021-2026)
- 12.3.4 Fujirebio(H.U. Group Holdings) Lyme Disease Testing Product Portfolio
- 12.3.5 Fujirebio(H.U. Group Holdings) Recent Developments
- 12.4 ZEUS Scientific
- 12.4.1 ZEUS Scientific Company Information
- 12.4.2 ZEUS Scientific Business Overview
- 12.4.3 ZEUS Scientific Revenue in Lyme Disease Testing Business (2021-2026)
- 12.4.4 ZEUS Scientific Lyme Disease Testing Product Portfolio
- 12.4.5 ZEUS Scientific Recent Developments
- 12.5 IGeneX
- 12.5.1 IGeneX Company Information
- 12.5.2 IGeneX Business Overview
- 12.5.3 IGeneX Revenue in Lyme Disease Testing Business (2021-2026)
- 12.5.4 IGeneX Lyme Disease Testing Product Portfolio
- 12.5.5 IGeneX Recent Developments
- 12.6 Thermo Fisher Scientific
- 12.6.1 Thermo Fisher Scientific Company Information
- 12.6.2 Thermo Fisher Scientific Business Overview
- 12.6.3 Thermo Fisher Scientific Revenue in Lyme Disease Testing Business (2021-2026)
- 12.6.4 Thermo Fisher Scientific Lyme Disease Testing Product Portfolio
- 12.6.5 Thermo Fisher Scientific Recent Developments
- 12.7 Everlywell
- 12.7.1 Everlywell Company Information
- 12.7.2 Everlywell Business Overview
- 12.7.3 Everlywell Revenue in Lyme Disease Testing Business (2021-2026)
- 12.7.4 Everlywell Lyme Disease Testing Product Portfolio
- 12.7.5 Everlywell Recent Developments
- 12.8 Oxford Immunotec Global PLC(PerkinElmer)
- 12.8.1 Oxford Immunotec Global PLC(PerkinElmer) Company Information
- 12.8.2 Oxford Immunotec Global PLC(PerkinElmer) Business Overview
- 12.8.3 Oxford Immunotec Global PLC(PerkinElmer) Revenue in Lyme Disease Testing Business (2021-2026)
- 12.8.4 Oxford Immunotec Global PLC(PerkinElmer) Lyme Disease Testing Product Portfolio
- 12.8.5 Oxford Immunotec Global PLC(PerkinElmer) Recent Developments
- 12.9 BioMerieux
- 12.9.1 BioMerieux Company Information
- 12.9.2 BioMerieux Business Overview
- 12.9.3 BioMerieux Revenue in Lyme Disease Testing Business (2021-2026)
- 12.9.4 BioMerieux Lyme Disease Testing Product Portfolio
- 12.9.5 BioMerieux Recent Developments
- 12.10 Bio-Rad Laboratories
- 12.10.1 Bio-Rad Laboratories Company Information
- 12.10.2 Bio-Rad Laboratories Business Overview
- 12.10.3 Bio-Rad Laboratories Revenue in Lyme Disease Testing Business (2021-2026)
- 12.10.4 Bio-Rad Laboratories Lyme Disease Testing Product Portfolio
- 12.10.5 Bio-Rad Laboratories Recent Developments
- 12.11 T2 Biosystems
- 12.11.1 T2 Biosystems Company Information
- 12.11.2 T2 Biosystems Business Overview
- 12.11.3 T2 Biosystems Revenue in Lyme Disease Testing Business (2021-2026)
- 12.11.4 T2 Biosystems Lyme Disease Testing Product Portfolio
- 12.11.5 T2 Biosystems Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst